9 May 2024

Anti JAKS giant cell arteritis Pharmaceuticals

New option for GCA on the cards

29 February 2024

Anti JAKS Dermatology

Can a new JAK inhibitor help with hives?

9 November 2023

Anti JAKS Dermatology Plaque psoriasis Psoriatic Athritis

Anti-JAKs safe in skin conditions

2 November 2023

Anti JAKS Rheumatoid Arthritis Vaccines

Shingrix works in at-risk JAKi patients, so why can’t they get it?

8 June 2023

Anti JAKS Biologics EULAR Rheumatoid Arthritis

JAKis don’t beat TNFis in high-risk patients

5 June 2023

Anti JAKS EULAR Rheumatoid Arthritis Sjogren Syndrom

Dual JAK1/TYK2 inhibitor outperforms tofacitinib

5 June 2023

Anti JAKS EULAR Rheumatoid Arthritis

CV and cancer risks with JAKi: EULAR perspectives

4 May 2023

Anti JAKS TGA

Black box warning but no smoking gun for class effect yet

23 March 2023

Anti JAKS Research

ORAL Surveillance risk groups narrow again

9 March 2023

Anti JAKS Psoriatic Athritis Rheumatoid Arthritis

More real-world reassurance for JAKi and cancer

2 March 2023

Anti JAKS Lupus

‘Back to the drawing board’ for JAKi in lupus

9 February 2023

Anti JAKS COVID-19 Dermatology podcast

JAKi and the brave new world of hair loss  

26 May 2022

Anti JAKS Conditions Pain

Anti-inflammatories could make back pain worse

28 April 2022

Anti JAKS Conditions

Dozens visit emergency department for NSAID anaphylaxis

3 March 2022

Anti JAKS Biologics COVID-19 Fibromyalgia

Antipyretics ‘reduce covid immunity, help fight TB’

17 June 2021

Anti JAKS Biologics Pain

NSAIDs outperform codeine for post-op pain